MY128337A - New combination of steroids - Google Patents

New combination of steroids

Info

Publication number
MY128337A
MY128337A MYPI97004698A MYPI9704698A MY128337A MY 128337 A MY128337 A MY 128337A MY PI97004698 A MYPI97004698 A MY PI97004698A MY PI9704698 A MYPI9704698 A MY PI9704698A MY 128337 A MY128337 A MY 128337A
Authority
MY
Malaysia
Prior art keywords
active ingredient
steroids
new combination
kit
composition
Prior art date
Application number
MYPI97004698A
Inventor
Trofast Jan
Ullman Anders
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of MY128337A publication Critical patent/MY128337A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

THE INVENTION PROVIDES A COMPOSITION OR KIT HAVING AS A FIRST ACTIVE INGREDIENT FORMOTEROL, OR A SALT OR SOLVATE DERIVATIVE THEREOF, AND HAVING AS A SECOND ACTIVE INGREDIENT BUDESONIDE, WHEREIN THE MOLAR RATIO OF THE FIRST ACTIVE INGREDIENT TO THE SECOND ACTIVE INGREDIENT IS FROM 1:30 TO 1:36, AND THE USE OF THE COMPOSITION AND KIT IN THE TREATMENT OF RESPIRATORY DISORDERS.
MYPI97004698A 1996-10-08 1997-10-07 New combination of steroids MY128337A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603669A SE9603669D0 (en) 1996-10-08 1996-10-08 New combination

Publications (1)

Publication Number Publication Date
MY128337A true MY128337A (en) 2007-01-31

Family

ID=20404167

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI97004698A MY128337A (en) 1996-10-08 1997-10-07 New combination of steroids

Country Status (18)

Country Link
EP (1) EP0871450A1 (en)
JP (1) JP2000502365A (en)
KR (1) KR19990071975A (en)
AR (1) AR013614A1 (en)
AU (1) AU715319B2 (en)
BR (1) BR9706822A (en)
CA (1) CA2239308A1 (en)
CZ (1) CZ176198A3 (en)
HU (1) HUP9901674A3 (en)
MY (1) MY128337A (en)
NO (1) NO982414L (en)
NZ (1) NZ330482A (en)
PL (1) PL327037A1 (en)
SE (1) SE9603669D0 (en)
SK (1) SK75198A3 (en)
TW (1) TW470647B (en)
WO (1) WO1998015280A1 (en)
ZA (1) ZA978889B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
SE9700136D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
SE9700134D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700133D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700135D0 (en) 1997-01-20 1997-01-20 Astra Ab New formulation
SK184799A3 (en) * 1997-06-27 2000-06-12 Astra Ab New combination of antiasthma medicaments
SE9703407D0 (en) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (en) 1998-06-11 1998-06-11 Astra Ab New use
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
SE9900834D0 (en) * 1999-03-09 1999-03-09 Astra Ab Novel combination
DE19921693A1 (en) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
FI20002216A0 (en) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Combination particles for asthma therapy
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
SE0200312D0 (en) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
SE527069C2 (en) 2003-06-19 2005-12-13 Mederio Ag Method and apparatus for administering drug powder
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
WO2008000042A1 (en) 2006-06-30 2008-01-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
WO2008102128A2 (en) 2007-02-19 2008-08-28 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
AU2010253770B9 (en) 2009-05-29 2015-02-12 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
RS62297B1 (en) 2011-11-23 2021-09-30 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
WO2013128283A2 (en) 2012-02-28 2013-09-06 Iceutica Holdings Inc. Bvi Inhalable pharmaceutical compositions
ITMI20130571A1 (en) 2013-04-10 2014-10-11 Zambon Spa PHARMACEUTICAL COMPOSITION CONTAINING BUDESONIDE AND FORMOTEROL
IT202000006442A1 (en) 2020-03-27 2021-09-27 Genetic S P A BUDESONIDE 21-PHOSPHATE SALTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48301A1 (en) * 1991-12-18 1998-04-17 Astra Ab New combination

Also Published As

Publication number Publication date
JP2000502365A (en) 2000-02-29
KR19990071975A (en) 1999-09-27
NZ330482A (en) 1999-11-29
HUP9901674A2 (en) 1999-09-28
TW470647B (en) 2002-01-01
ZA978889B (en) 1998-04-08
WO1998015280A1 (en) 1998-04-16
BR9706822A (en) 1999-03-23
AU715319B2 (en) 2000-01-20
SK75198A3 (en) 1998-11-04
PL327037A1 (en) 1998-11-09
AU4578297A (en) 1998-05-05
HUP9901674A3 (en) 2001-04-28
SE9603669D0 (en) 1996-10-08
AR013614A1 (en) 2001-01-10
NO982414D0 (en) 1998-05-27
CA2239308A1 (en) 1998-04-16
NO982414L (en) 1998-05-27
CZ176198A3 (en) 1998-09-16
EP0871450A1 (en) 1998-10-21

Similar Documents

Publication Publication Date Title
SE9603669D0 (en) New combination
GR1003011B (en) Novel formulation
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
CA2259621A1 (en) Isocoumarin derivatives and their use in medicines
AU3497295A (en) Compositions and methods for the treatment of body weight disorders, including obesity
WO2002000209A3 (en) Gabapentin analogues for sleep disorders
EE05661B1 (en) Use of a Formoterol and Budesonide Composition for the Prevention or Treatment of Asthma-Related Conditions
ES2182357T3 (en) NEW USE OF BUDESONIDE AND FORMOTEROL.
CA2199844A1 (en) Compositions for the treatment of skin disorders
EP0902789A4 (en)
CA2166332A1 (en) Antiglucocorticoid steroids for the treatment of anxiety disorders
BG102667A (en) Diosgenine-containing composition
FR2673375B1 (en)
EP0373771A3 (en) New pharmaceutical uses for cystatins
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
GB2388777A (en) Compositions containing gangliosides for use in the treatment of skin disorders
GEP20043286B (en) Dual Inhibitors of Cholesteryl Ester and Wax Ester Synthesis for Sebaceous Gland Disorders
GR1002576B (en) Pharmaceutical compositions and a process for the preparation thereof.
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
EP1101493A3 (en) New combination of formoterol and budesonide
MD980129A (en) Antiherpetic remedy
WO2002036105A3 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
AU4448497A (en) Novel 6 or 7 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents
SE9902673D0 (en) New composition
IL125983A0 (en) Pharmaceutical composition comprising factor xiiia